1[1]Berg J,Christoph T,Fellier H.Theanalqesic NSAID Lornoxicam inbibirs cox-1/cox-2,iNOs and the formation of IL-6 in vitro[J].Nannyn-Schmiod Arch pharmacol,1998,358(suppl.2):R716.
2[2]Berg J,christoph T,Widerna M,Bodenteich A.Isoenzyme-Specific Cyclooxygenase inhibitirs:A whole cen assay ayatem using the human erythrolukemic cenrl line HEL and the human monocytic ceril line monomai6[J].J pharmacol Toxicaol meth,1997,37:179-86.
3[3]Turner P,Johnston-A.clinical pharmacokinetic studies with lornoxicam[J].Postgracl Med J,1996(suppl.4):28.
4[4]Pruss T P,stroissing H,Radhifer WS,et al.overview of the pharmacological properties,pharmacokhetics and animal gafety assessment of lornoxicam[J].Postgrad Med J,1990,66(suppl.4):28.
5[5]Staunstrup H,Ovesen UY,Elbaek KJ,Larsen U,Kroner K.Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain[J].J xlin Pharmacol,1999,39(8):834-41.
6[6]Norholt SE,sindet-pedersen S,Larsen U,et al.Pain control after dental surgery:a double blind,randomized trial of lornoxic am versus morphine pain,1996,Oct;67(2-3):335-43.
7[7]Norholt SE,Sindet-pedersen S,Buqqe C,et al.A randomized,double-blind,placdbo controlled,dose-response study of the analpesic effect of lomoxicam after surqical removal of mandibular third molars[J].T slin oharmacol,1995,35(6):606-14.
8[8]Rosenow DE,van krieken F,stolke D,et al.Intruvenous adminsrrstion of lomxicam,a new NSAID,and pethidme for postoperation pain[J].Clin Drug znvest,1996,11(1):11.
1Pruss TP, Stroissnig H, Radhofer Welte S, et al. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lomoxicam[ J ]. Postgrad Med J, 1990, 66 (Suppl 4):S18 - S21.
2Berry H, Bird HA, Black C, et al. A double blind, multicentre,placebo controlled trail of lornoxicarn in patients with osteoarthritis of the hip and knee[J]. Ann Rheum Dis, 1992, 52(2) :238 -242.
3Bemstein RM, Frenzel W. A comparative study of two dosage regimens of lornoxicarn and a standard dosage of naproxen in patients with rheumatoid arthritis[J ]. Eur J Clin Res, 1995, 7 ( 5 ): 259 -273.
4McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing[ J ]. Pain, 1994, 59( 1 ): 6 - 43.
5Rosernow DE, Albrechtsen M, Stolke D. A comparison of patientcontrolled analgesia with lomoxicam versus morphine in patients undergoing lumbar disk surgery[J ]. Anesthesia Analgesia, 1998,86(5): 1045 - 1050.
6Pruss TP,Stoiβnig H,Radhofer Welte S,et al.Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam[].Postgraduate Medical Journal.1990
7Olkkola KT,Brunetto AV,Mattila MJ.Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents[].Clinical Pharmacokinetics.1994
8Nuutinen LS,Laitinen JO,Salomaki TE.A risk-benefit appraisal of injectable NSAIDs in the management of postoper-ative pain[].Drug Safety.1993
9Kullich W,Klein G.Influence of the nonsteroidal anti-inflammatory drug lornoxicam on the secretion of the endogenous opiate peptides dynorphin andβ-endorphin[].Aktuelle Rheumatologie.1992
10Detlef ER,Morten A,Diet mars.A comparison of patient-con-trolled analgesia withlornoxicam versus morphine in patients un-dergoing lumbar disk surgery[].Anesthesia and Analgesia.1998
